Tirzepatide 15mg

Tirzepatide is a novel synthetic peptide that functions as a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It is a 39-amino acid linear peptide engineered to enhance stability and resistance to enzymatic degradation, with a prolonged half-life suitable for once-weekly administration in research models.

Tirzepatide has gained significant interest in metabolic research due to its dual receptor activity, which mimics the natural incretin hormones involved in glycemic control and energy homeostasis. In preclinical studies, Tirzepatide has been shown to enhance insulin secretion in a glucose-dependent manner, reduce glucagon levels, delay gastric emptying, and significantly suppress appetite. These effects contribute to improved glucose tolerance and pronounced body weight reduction in animal models.

Additionally, Tirzepatide has demonstrated promising effects on lipid metabolism, inflammation markers, and insulin sensitivity, indicating potential cardiovascular and hepatic benefits. Its unique mechanism offers synergistic effects not observed with single-pathway peptides, positioning Tirzepatide as a powerful candidate for studying complex metabolic disorders.

Due to its multifaceted biological actions, Tirzepatide is currently the subject of extensive research in the areas of obesity, type 2 diabetes, and cardiometabolic health.